Filing Flows › Comparisons › TKNO vs ICCC
Alpha Teknova vs Immucell: TKNO and ICCC compared
Alpha Teknova is the larger company: $12.7M of revenue in its latest quarter (Q3 2026) against $7.2M for Immucell (Q2 2026). Alpha Teknova is growing faster (+22% against +12% a year earlier). Immucell is more profitable, with an operating margin of 26.9% against -25.2%.
Where the money goes: TKNO and ICCC
Alpha Teknova (TKNO) · Q3 2026
Alpha Teknova, Q3 2026: revenue $12.7M (+22% year over year), operating margin -25.2%, net loss $3.5M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
Immucell (ICCC) · Q2 2026
Immucell, Q2 2026: revenue $7.2M (+12% year over year), operating margin 26.9%, net earnings $1.8M, operating cash flow $3.0M. The chart follows the revenue to costs, profit and cash.
| Alpha Teknova (TKNO) | Immucell (ICCC) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $12.7M | $7.2M |
| Revenue growth, Y/Y | +22% | +12% |
| Gross margin | — | 33.9% |
| Operating margin | -25.2% | 26.9% |
| Net earnings | −$3.5M | $1.8M |
| Net margin | -27.5% | 25.5% |
| Operating cash flow | −$1.3M | $3.0M |
| Free cash flow | — | $2.3M |
Where the revenue comes from
Alpha Teknova
- Lab Essentials: $9.0M (71%)
- Clinical Solutions: $3.2M (25%)
- Other Product: $502K (4%)
Questions
Which is bigger, Alpha Teknova or Immucell?
Alpha Teknova is the larger company: $12.7M of revenue in its latest quarter (Q3 2026) against $7.2M for Immucell (Q2 2026).
Is Alpha Teknova or Immucell growing faster?
Alpha Teknova is growing faster (+22% against +12% a year earlier).
Which is more profitable, Alpha Teknova or Immucell?
Immucell is more profitable, with an operating margin of 26.9% against -25.2%.
More: Alpha Teknova earnings · how Alpha Teknova makes money · Immucell earnings · how Immucell makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.